 Alain Cuna
Concepts (123)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bronchopulmonary Dysplasia | 15 | 2022 | 41 | 6.110 |
Why?
| | Enterocolitis, Necrotizing | 11 | 2023 | 71 | 5.630 |
Why?
| | Infant, Premature | 12 | 2023 | 85 | 2.660 |
Why?
| | Infant, Newborn | 24 | 2023 | 828 | 2.500 |
Why?
| | Infant, Newborn, Diseases | 4 | 2023 | 34 | 2.490 |
Why?
| | Glucocorticoids | 6 | 2021 | 30 | 2.470 |
Why?
| | Dexamethasone | 4 | 2022 | 30 | 1.520 |
Why?
| | Intestines | 2 | 2021 | 26 | 1.500 |
Why?
| | Humans | 26 | 2023 | 6797 | 1.350 |
Why?
| | Genetic Predisposition to Disease | 3 | 2018 | 224 | 1.250 |
Why?
| | Infant | 13 | 2023 | 1449 | 1.230 |
Why?
| | Retrospective Studies | 12 | 2022 | 1332 | 1.100 |
Why?
| | Gastrointestinal Microbiome | 2 | 2021 | 9 | 0.970 |
Why?
| | Toll-Like Receptors | 2 | 2023 | 12 | 0.970 |
Why?
| | Receptors, Interleukin-1 | 2 | 2020 | 9 | 0.900 |
Why?
| | Ultrasonography, Doppler | 2 | 2020 | 11 | 0.860 |
Why?
| | Ultrasonography | 2 | 2022 | 43 | 0.850 |
Why?
| | Steroids | 2 | 2020 | 14 | 0.820 |
Why?
| | Bacteria | 1 | 2021 | 9 | 0.790 |
Why?
| | Quality Improvement | 2 | 2020 | 60 | 0.790 |
Why?
| | Respiration, Artificial | 2 | 2018 | 17 | 0.770 |
Why?
| | Animals | 7 | 2023 | 664 | 0.720 |
Why?
| | Gestational Age | 5 | 2022 | 66 | 0.700 |
Why?
| | Anti-Inflammatory Agents | 1 | 2018 | 11 | 0.690 |
Why?
| | Pulmonary Alveoli | 2 | 2015 | 9 | 0.680 |
Why?
| | Gene Expression Regulation, Developmental | 2 | 2016 | 55 | 0.670 |
Why?
| | Female | 11 | 2022 | 3599 | 0.670 |
Why?
| | Genetic Loci | 1 | 2018 | 37 | 0.660 |
Why?
| | Male | 10 | 2019 | 3328 | 0.660 |
Why?
| | Genotype | 2 | 2018 | 401 | 0.630 |
Why?
| | Airway Extubation | 1 | 2017 | 1 | 0.630 |
Why?
| | Risk Assessment | 1 | 2018 | 137 | 0.620 |
Why?
| | Infant, Extremely Premature | 4 | 2019 | 13 | 0.610 |
Why?
| | Vaccination | 1 | 2017 | 68 | 0.610 |
Why?
| | Respiratory Distress Syndrome, Newborn | 1 | 2016 | 8 | 0.590 |
Why?
| | Genome-Wide Association Study | 2 | 2016 | 183 | 0.580 |
Why?
| | Infant, Premature, Diseases | 1 | 2016 | 23 | 0.580 |
Why?
| | Length of Stay | 1 | 2017 | 243 | 0.570 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2014 | 6 | 0.500 |
Why?
| | DNA Methylation | 1 | 2015 | 130 | 0.500 |
Why?
| | Hypertension, Pulmonary | 1 | 2014 | 10 | 0.490 |
Why?
| | Missouri | 3 | 2018 | 78 | 0.460 |
Why?
| | Signal Transduction | 3 | 2023 | 111 | 0.430 |
Why?
| | Probiotics | 2 | 2021 | 8 | 0.390 |
Why?
| | Inflammation | 3 | 2020 | 51 | 0.360 |
Why?
| | Mice | 4 | 2020 | 312 | 0.360 |
Why?
| | Prognosis | 2 | 2021 | 213 | 0.340 |
Why?
| | Tracheostomy | 2 | 2019 | 11 | 0.340 |
Why?
| | Intestinal Mucosa | 2 | 2020 | 36 | 0.320 |
Why?
| | Drug Administration Schedule | 2 | 2018 | 41 | 0.320 |
Why?
| | Sensitivity and Specificity | 2 | 2018 | 147 | 0.320 |
Why?
| | Treatment Outcome | 2 | 2018 | 667 | 0.270 |
Why?
| | Cohort Studies | 2 | 2018 | 274 | 0.270 |
Why?
| | Animals, Newborn | 3 | 2020 | 53 | 0.260 |
Why?
| | Mice, Inbred C57BL | 3 | 2020 | 89 | 0.260 |
Why?
| | Adrenal Cortex Hormones | 2 | 2022 | 34 | 0.250 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2016 | 342 | 0.240 |
Why?
| | Adult | 2 | 2018 | 1259 | 0.230 |
Why?
| | Cytokines | 2 | 2020 | 48 | 0.220 |
Why?
| | Apoptosis | 2 | 2020 | 51 | 0.220 |
Why?
| | Infant Formula | 2 | 2020 | 15 | 0.220 |
Why?
| | Intensive Care, Neonatal | 1 | 2022 | 7 | 0.220 |
Why?
| | Feasibility Studies | 1 | 2022 | 67 | 0.220 |
Why?
| | Lung Diseases | 1 | 2022 | 26 | 0.210 |
Why?
| | Risk Factors | 2 | 2021 | 470 | 0.200 |
Why?
| | Infant, Very Low Birth Weight | 1 | 2021 | 10 | 0.200 |
Why?
| | Fecal Microbiota Transplantation | 1 | 2021 | 2 | 0.200 |
Why?
| | Prebiotics | 1 | 2021 | 2 | 0.200 |
Why?
| | Dysbiosis | 1 | 2021 | 4 | 0.200 |
Why?
| | Host-Pathogen Interactions | 1 | 2021 | 8 | 0.200 |
Why?
| | Administration, Inhalation | 1 | 2020 | 19 | 0.200 |
Why?
| | Kupffer Cells | 1 | 2020 | 3 | 0.190 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2020 | 7 | 0.190 |
Why?
| | Immunity, Innate | 2 | 2017 | 16 | 0.190 |
Why?
| | Dietary Supplements | 1 | 2020 | 20 | 0.190 |
Why?
| | Ileum | 1 | 2020 | 18 | 0.180 |
Why?
| | Language Development | 1 | 2019 | 3 | 0.180 |
Why?
| | Cognition | 1 | 2019 | 31 | 0.180 |
Why?
| | Prednisolone | 1 | 2019 | 4 | 0.180 |
Why?
| | Mutation | 2 | 2017 | 199 | 0.170 |
Why?
| | Child | 3 | 2022 | 3257 | 0.160 |
Why?
| | Patient Outcome Assessment | 1 | 2018 | 8 | 0.160 |
Why?
| | Survival Analysis | 1 | 2018 | 47 | 0.160 |
Why?
| | Severity of Illness Index | 1 | 2018 | 144 | 0.160 |
Why?
| | Predictive Value of Tests | 1 | 2017 | 104 | 0.160 |
Why?
| | Toll-Like Receptor 4 | 1 | 2017 | 13 | 0.160 |
Why?
| | Treatment Failure | 1 | 2017 | 18 | 0.160 |
Why?
| | Immunization Schedule | 1 | 2017 | 7 | 0.160 |
Why?
| | Infant, Extremely Low Birth Weight | 2 | 2014 | 10 | 0.160 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2017 | 34 | 0.150 |
Why?
| | Logistic Models | 1 | 2017 | 93 | 0.150 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 28 | 0.150 |
Why?
| | Molecular Targeted Therapy | 1 | 2016 | 11 | 0.150 |
Why?
| | Hyperoxia | 1 | 2015 | 5 | 0.140 |
Why?
| | MicroRNAs | 1 | 2015 | 31 | 0.140 |
Why?
| | Genetic Variation | 1 | 2016 | 167 | 0.130 |
Why?
| | Gastrointestinal Contents | 1 | 2014 | 1 | 0.130 |
Why?
| | DNA | 1 | 2014 | 42 | 0.130 |
Why?
| | Epigenesis, Genetic | 1 | 2015 | 94 | 0.130 |
Why?
| | Enteral Nutrition | 1 | 2014 | 65 | 0.120 |
Why?
| | Disease Models, Animal | 2 | 2017 | 74 | 0.070 |
Why?
| | Chronic Disease | 1 | 2022 | 104 | 0.050 |
Why?
| | Pilot Projects | 1 | 2022 | 128 | 0.050 |
Why?
| | Canada | 1 | 2021 | 31 | 0.050 |
Why?
| | Hospitals | 1 | 2021 | 39 | 0.050 |
Why?
| | Hospitals, Pediatric | 1 | 2022 | 183 | 0.050 |
Why?
| | Early Diagnosis | 1 | 2020 | 34 | 0.050 |
Why?
| | Language Development Disorders | 1 | 2019 | 3 | 0.050 |
Why?
| | Cognition Disorders | 1 | 2019 | 13 | 0.050 |
Why?
| | Child Development | 1 | 2019 | 42 | 0.040 |
Why?
| | Phosphorylation | 1 | 2017 | 27 | 0.040 |
Why?
| | Mice, Transgenic | 1 | 2017 | 33 | 0.040 |
Why?
| | Lipopolysaccharides | 1 | 2017 | 21 | 0.040 |
Why?
| | Child, Preschool | 1 | 2022 | 1503 | 0.040 |
Why?
| | Fibroblasts | 1 | 2015 | 26 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2015 | 76 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2015 | 56 | 0.030 |
Why?
| | Perinatal Death | 1 | 2014 | 1 | 0.030 |
Why?
| | Intestinal Perforation | 1 | 2014 | 12 | 0.030 |
Why?
| | Milk, Human | 1 | 2014 | 21 | 0.030 |
Why?
| | Survival Rate | 1 | 2014 | 84 | 0.030 |
Why?
| | Incidence | 1 | 2014 | 132 | 0.030 |
Why?
| | United States | 1 | 2014 | 656 | 0.030 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|